Epstein Secrets

rs, so the amount could prove to be significantly lower than that. Also, other companies are likely to launch their own PCSK9 drugs soon, including Amgen, which is expecting an FDA decision later this month. As new competitors roll-out their products, it should result in larger gross to net price cuts

From: Sultan Sulayem To: [email protected] Subject: Praluent's sales could eclipse $7 billion. Date: Sun, 09 Aug 2015 18:11:11 +0000 Will Regeneron's New Drug Break The Bank? Regeneron and Sanoties newly-lau

es could eclipse $7 billion. Date: Sun, 09 Aug 2015 18:11:11 +0000 Will Regeneron's New Drug Break The Bank? Regeneron and Sanoties newly-launched Praluent could cause healthcare costs to soar. Todd Campbell TMFEBCapital Aug 5, 2015 at 8:03AM ,,,Money Inside Pills Flickr User Chris Potter Source: Fl

he gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition

ainst heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line. "Obvi

low me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being ad

the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition

had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w

the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition

had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w